Latest news with #SpecialMeeting
Yahoo
14-07-2025
- Business
- Yahoo
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
Special Meeting was validly adjourned until the appropriate court can make a final decision on the validity of the PIPE shares SAIF's "announcement" about voting results demonstrates blatant disregard for the law and the Company's bylaws and a repeated pattern of self-serving and unlawful actions by the Imposter Former Board Current Board remains the only valid board of directors of the Company and will continue to govern SINOVAC BEIJING, July 09, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading biopharmaceutical company in China, categorically rejects the recent deceptive and illegal claims by SAIF and the Imposter Former Board that it purported to "reconvene" the adjourned Special Meeting of Shareholders (the "Special Meeting") and announced sham voting results of the shareholder proposals. At the July 8, 2025 Special Meeting, SINOVAC Chairman Chiang Li validly adjourned the meeting, to preserve the integrity of the Special Meeting and protect shareholder interests, pending the resolution of litigation in Antigua related to the validity of the 11.8 million shares purportedly issued following an invalid private investment in public equity ("PIPE") to Advantech/Prime and Vivo Capital (together known as the "Dissenting Investor Group"). SINOVAC shareholders should ignore SAIF's lies. SAIF and the Imposter Former Board did NOT have the authority or any legal basis to "reconvene" the Special Meeting following the valid adjournment. SAIF's self-declaration of a final tally of shareholder votes was a complete sham. SINOVAC is evaluating its legal remedies with respect to the deceptive and unlawful conduct of SAIF and the Imposter Former Board, including with authorities in Antigua and the United States. William P. Fiske, Head of M&A and Contested Situations at Georgeson, SINOVAC's proxy solicitor, stated, "At the time of the Special Meeting, according to our preliminary voting tallies, the Company's White Proxy Card secured overwhelming support from valid shareholders for the current SINOVAC Board. Had the injunction granted by the Antigua Court not been temporarily stayed, the shareholders would have voted in favor of the current SINOVAC Board." SAIF and the Gold Proxy Card secured little support outside of the same incumbent group that has propped up the Imposter Former Board to seize control of SINOVAC and destroy value for all valid common shareholders – just as they did during the seven years that they held SINOVAC hostage. The Imposter Former Board's refusal to acknowledge the lawful adjournment of the Special Meeting and their fabrication of the meeting's outcome are wholly illegal, invalid, and reckless. The rightful SINOVAC Board remains in place and will continue to govern the Company. The Board has a duty to implement the UK Privy Council's judgment and order, which includes resolving the question of the validity of the PIPE shares. The Board will continue to fight on behalf of all SINOVAC shareholders and remains committed to its mission of restoring fairness, delivering value and protecting the rights of all valid shareholders. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Sign in to access your portfolio
Yahoo
14-07-2025
- Business
- Yahoo
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group's deceptive claims of a "continuation of the Special Meeting" and a pretend "Board" are fake and without legal basis Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company BEIJING, July 11, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company") today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the "Special Meeting"): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity ("PIPE") to Advantech/Prime and Vivo Capital (together known as the "Dissenting Investor Group"). The adjournment has been recognized by the independent Inspector of Elections who has the sole authority to announce and certify the results of the Special Meeting. SAIF's false claim that a "continuation of the Special Meeting" occurred is intentionally deceptive and entirely illegal under the Company's bylaws and Antiguan law. Immediately after the Special Meeting was validly adjourned and the virtual meeting was terminated, a group of lawyers representing SAIF and the Dissenting Investor Group purportedly self-organized an invalid, pretend special meeting at an unannounced location and time. This group did not give advance notice to valid shareholders or give them an option to attend, and they did not contact SINOVAC Chairman Chiang Li, the only authorized chair for the Special Meeting. No inspector of elections presided over the pretend special meeting. The current SINOVAC Board understands Mr. Yuk Lam Lo attended the invalid meeting with the understanding that he had no authority to chair any such shareholder meeting. At the pretend special meeting, this group announced pretend "voting results" from a "vote" that did not take place due to the valid adjournment. The following day, SAIF and the Dissenting Investor Group held a pretend meeting to elect a pretend Chairman. Valid SINOVAC shareholders are admonished to ignore these theatrics. The Board, consisting of Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven Borho and Mr. Geoffrey Hsu, retains full authority to run SINOVAC. None of the pretend board's rogue actions are valid or legal. SAIF and the Dissenting Investor Group will be held responsible. At the time of the Special Meeting, the injunction granted by the Eastern Caribbean Supreme Court of Antigua and Barbuda (the "Antigua High Court") on July 7, 2025 – prohibiting the PIPE shares from voting at the meeting – had not been overturned. While the Eastern Caribbean Court of Appeal temporarily stayed the injunction order, the stay is in place until a hearing is held to determine whether such stay should have been granted. On July 11, 2025, Judge Bakre of the Antigua High Court issued a ruling, which stated that granting a stay would make a "mockery" of this case. There are ongoing legal proceedings in Antigua to determine the validity of the PIPE shares. The current Board will reconvene the Special Meeting once this issue is resolved by the proper court. During this period, voting is unavailable. All valid shareholders will have their vote counted at the validly reconvened Special Meeting. The current SINOVAC Board remains in place, is governing the Company, and is executing on its stated priorities. These include dividend distributions according to its previously announced policy, in addition to the ongoing payment of the US$55.00 per common share special cash dividend paid to valid shareholders or their brokers beginning on July 7, 2025, working with NASDAQ to resume trading, the appointment of a new auditor, and exploring a future listing on the Stock Exchange of Hong Kong to promote liquidity and maximize value creation. The SINOVAC Board urges all shareholders to rely only on official communications from the rightful Board for accurate information. The Board remains committed to transparency and the rule of law and will provide further updates as developments occur. For ongoing updates and further information, please visit About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media ContactFGS GlobalSinovac@
Yahoo
15-04-2025
- Business
- Yahoo
Dexterra Announces Date for Q1 Results and Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - April 15, 2025) - Dexterra Group Inc. (TSX: DXT) ("Dexterra") announces that it intends to release its Q1 2025 results on May 6, 2025 after market close and has scheduled a conference call and webcast to begin promptly at 8:30 a.m. Eastern time on May 7, 2025. A presentation will be posted on the Dexterra website at on May 6, 2025 to be reviewed on the conference call. The conference call dial in number is 1-844-763-8274. A live webcast of the conference call will be accessible on Dexterra's website at by selecting the Q1 2025 Results webcast link. An archived recording of the conference call will be available approximately one hour after the completion of the call until June 7, 2025 by dialing 1-855-669-9685, passcode 5939979. Annual and Special Meeting Dexterra's Annual and Special Meeting (the "Meeting") will be held on Wednesday, May 7, 2025, at 10:00 a.m. Eastern time, in a virtual only format via live audio webcast at or accessible on our website at by selecting 2025 Annual and Special Meeting webcast link. Details on how to vote and access the Meeting can be found in the Management Information Circular, which is available on the Dexterra website at under the Company's profile at and at TSX Trust Company's website at About Dexterra Dexterra employs over 9,000 people, delivering a range of support services for the creation, management, and operation of infrastructure across Canada and the U.S. Powered by people, Dexterra brings best-in-class regional expertise to every challenge and delivers innovative solutions, giving clients confidence in their day-to-day operations. Activities include a comprehensive range of integrated facilities management services, industry-leading workforce accommodation solutions, and other support services for diverse clients in the public and private sectors. For further information contact:Denise Achonu, CFOHead office: Airway Centre, 5925 Airport Rd., Suite 1000Mississauga, Ontario L4V 1W1Telephone: (905) 270-1964 You can also visit our website at To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
18-02-2025
- Business
- Yahoo
Capital One and Discover Stockholders Approve Capital One's Proposed Acquisition of Discover
MCLEAN, Va., February 18, 2025--(BUSINESS WIRE)--Capital One Financial Corporation (NYSE: COF) and Discover Financial Services (NYSE: DFS) today announced that each company's respective stockholders have voted to approve Capital One's previously announced acquisition of Discover at each company's Special Meeting of Stockholders (the "Special Meeting"). Special Meeting Stockholder Vote Results Capital One: More than 99.8% of the Capital One shares voted at the Capital One Special Meeting were voted in favor of the transaction, representing 85.1% of the total number of outstanding shares of Capital One common stock as of December 27, 2024, the record date for Capital One's Special Meeting. Discover: More than 99.3% of the Discover shares voted at the Discover Special Meeting were voted in favor of the transaction, representing approximately 81.6% of the total number of outstanding shares of Discover common stock as of December 27, 2024, the record date for Discover's Special Meeting. Stockholder approval marks an important milestone in the process to combine Capital One and Discover, two mission-driven companies with proven track records of delivering best-in-class solutions for consumers, small businesses, merchants and communities. Additional Merger Agreement Conditions Capital One anticipates that the transaction will close in early 2025, subject to approval by the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency, and other customary closing conditions. As previously announced, the Delaware State Bank Commissioner approved Capital One's proposed acquisition of Discover on December 18, 2024. Further information on Capital One's agreement to acquire Discover can be found at About Capital One Capital One Financial Corporation ( is a financial holding company which, along with its subsidiaries, had $362.7 billion in deposits and $490.1 billion in total assets as of December 31, 2024. Headquartered in McLean, Virginia, Capital One offers a broad spectrum of financial products and services to consumers, small businesses and commercial clients through a variety of channels. Capital One, N.A. has branches and Cafés located primarily in New York, Louisiana, Texas, Maryland, Virginia and the District of Columbia. A Fortune 500 company, Capital One trades on the New York Stock Exchange under the symbol "COF" and is included in the S&P 100 index. Additional information about Capital One can be found at Capital One About at About Discover Discover Financial Services (NYSE: DFS) is a digital banking and payment services company with one of the most recognized brands in U.S. financial services. Since its inception in 1986, the company has become one of the largest card issuers in the United States. Discover issues the Discover® card, America's cash rewards pioneer, and offers personal loans, home loans, checking and savings accounts and certificates of deposit through its banking business. It operates the Discover Global Network® comprised of Discover Network, with millions of merchants and cash access locations; PULSE®, one of the nation's leading ATM/debit networks; and Diners Club International®, a global payments network with acceptance around the world. For more information, visit Forward Looking Statements Information in this communication, other than statements of historical facts, may constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the benefits of the proposed transaction between Capital One Financial Corporation ("Capital One") and Discover Financial Services ("Discover"), statements related to the expected timing of the completion of the transaction, statements about the combined company's plans, objectives, expectations and intentions, and other statements that are not historical facts. Forward-looking statements may be identified by terminology such as "may," "will," "should," "targets," "scheduled," "plans," "intends," "goal," "anticipates," "expects," "believes," "forecasts," "outlook," "estimates," "potential," or "continue" or negatives of such terms or other comparable terminology. All forward-looking statements are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of Capital One or Discover to differ materially from any results expressed or implied by such forward-looking statements. Such factors include, among others, (1) the risk that the cost savings and any revenue synergies and other anticipated benefits from the transaction may not be fully realized or may take longer than anticipated to be realized, the risk that revenues following the transaction may be lower than expected and/or the risk that certain expenses, such as the provision for credit losses, of Discover, or Capital One following the transaction, may be greater than expected, (2) disruption to the parties' businesses as a result of the announcement and pendency of the transaction, (3) the risk that the integration of Discover's business and operations into Capital One, including the integration into Capital One's compliance management program, will be materially delayed or will be more costly or difficult than expected, or that Capital One is otherwise unable to successfully integrate Discover's businesses into its own, including as a result of unexpected factors or events, (4) the possibility that the requisite regulatory approvals are not received or other conditions to the closing are not satisfied on a timely basis or at all, or are obtained subject to conditions that are not anticipated (and the risk that requisite regulatory approvals may result in the imposition of conditions that could adversely affect Capital One or the expected benefits of the transaction following the closing of the transaction), (5) reputational risk and the reaction of each company's customers, suppliers, employees or other business partners to the transaction, (6) the failure of the closing conditions in the merger agreement to be satisfied, or any unexpected delay in completing the transaction or the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, (7) the dilution caused by the issuance of additional shares of Capital One's common stock in connection with the transaction, (8) the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events, (9) risks related to management and oversight of the expanded business and operations of Capital One following the transaction due to the increased size and complexity of its business, (10) the possibility of increased scrutiny by, and/or additional regulatory requirements of, governmental authorities as a result of the transaction or the size, scope and complexity of Capital One's business operations following the transaction, (11) the outcome of any legal or regulatory proceedings that may be currently pending or later instituted against Capital One before or after the transaction, or against Discover, (12) the risk that expectations regarding the timing, completion and accounting and tax treatments of the transaction are not met, (13) the risk that any announcements relating to the transaction could have adverse effects on the market price of Capital One's common stock, (14) certain restrictions during the pendency of the transaction, (15) the diversion of management's attention from ongoing business operations and opportunities, (16) Capital One's and Discover's success in executing their respective business plans and strategies and managing the risks involved in the foregoing, (17) effects of the announcement, pendency or completion of the transaction on Capital One's or Discover's ability to retain customers and retain and hire key personnel and maintain relationships with Capital One's and Discover's suppliers and other business partners, and on Capital One's and Discover's operating results and businesses generally, (18) general competitive, economic, political and market conditions and other factors that may affect future results of Capital One and Discover, including changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; changes in interest rates and capital markets; inflation; customer borrowing, repayment, investment and deposit practices; the impact, extent and timing of technological changes; capital management activities and (19) any other factors that may affect Capital One's future results or the future results of Discover; and other actions of the Federal Reserve Board and legislative and regulatory actions and reforms. Additional factors which could affect future results of Capital One and Discover can be found in Capital One's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and Discover's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K (and any amendments to those documents), in each case filed with the SEC and available on the SEC's website at Capital One and Discover disclaim any obligation and do not intend to update or revise any forward-looking statements contained in this communication, which speak only as of the date hereof, whether as a result of new information, future events or otherwise, except as required by federal securities laws. View source version on Contacts Media RelationsSie Soheili Matthew Towson matthewtowson@ Investor Relations Danielle Dietz Erin Stieber investorrelations@ Sign in to access your portfolio
Associated Press
06-02-2025
- Business
- Associated Press
Datametrex Announces Share Consolidation
TORONTO, ON / ACCESS Newswire / February 6, 2025 / Datametrex AI Limited (the 'Company' or 'Datametrex') (TSXV:DM)(FSE:D4G)(OTCQB:DTMXF) announces a proposed consolidation of its common shares on the basis of one (1) new common share for every existing thirty (30) common shares (the 'Consolidation'), subject to regulatory approval, including approval of the TSX Venture Exchange (the 'TSXV'). The Consolidation was approved by the shareholders of the Company at the Annual and Special Meeting held on November 13, 2024. The management believes that the Consolidation is necessary to optimize the capital structure of the Company and to attract financing. Subject to approval of the TSXV, the Consolidation is anticipated to be completed in the immediate future. Where the exchange results in a fractional share, any fractional share that is less than 1/2 of one post-consolidation Common Share will be cancelled and each fractional share that is at least 1/2 of one post-consolidation Common Share will be rounded up to one whole post-consolidation Common Share. The Company's new ISIN number will be CA23809L2075. The Company will not undergo a name change at the time of Consolidation. Accordingly, the trading symbol of the Company's common shares on the TSXV will remain as 'DM'. A letter of transmittal will be mailed to registered shareholders providing instructions on how to exchange share certificates representing pre-Consolidation Shares for new share certificates or direct registration advice statements (DRS) representing post-Consolidation Shares to which they are entitled as a result of the Consolidation. No action is required by non-registered shareholders (shareholders who hold their common shares through an intermediary) to effect the Consolidation. As on date, there are 630,080,158 pre-Consolidation shares outstanding. Following the Consolidation, there are expected to be 21,002,671 post-Consolidation shares outstanding. About Datametrex Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, Healthcare, and Mobile Gaming. The Company excels in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology. For more on Datametrex, please visit our Company website. For Additional Information Paul Haber, C.P.A., C.A., C. Dir CEO & Chairman (416) 318-6501 Disclaimer Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release Forward-Looking Statements This press release may contain certain forward-looking information and statements ('forward-looking information') within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words 'believes', "anticipates', 'plans', 'intends', 'will', 'should', 'expects', 'continue', 'estimate', 'forecasts' and other similar expressions. Forward-looking information in this press release includes, but is not limited to, expectations regarding the Consolidation, the new ISIN of the Company being effective as of the expected effective date, and the Company receiving regulatory approvals to complete the Consolidation. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
